Metformin in the prevention of colorectal cancer with diabetes mellitus

Author:

Druk I. V.1ORCID,Lyalyukova E. A.1,Fadeeva E. A.1ORCID

Affiliation:

1. Omsk State Medical University of the Ministry of Health of the Russian Federation

Abstract

The purpose of the review is to present an analysis of current literature data on the prospects of using the oncoprotective effect of metformin in colorectal cancer. Metformin is a drug with a long history, it is a first-line drug for the treatment of type 2 diabetes mellitus (DM2), as well as the most commonly prescribed drug worldwide. Modern researches show that in addition to its role in glucose control, metformin can reduce the risk and mortality from some malignancies and improve the response of patients with DM2 to certain types of cancer treatment. Accumulated data indicate that metformin could be a candidate drug for drug prevention of colorectal cancer.

Publisher

LLC Global Media Technology

Subject

Gastroenterology,Hepatology

Reference67 articles.

1. Cimmerman Ya. S. Colorectal cancer: state-of-the-art. RJGHC. 2012. Vol. 22 no. 4, pp.5-16. (In Russian) @@Tsimmerman Ya. S. Kolorektal'nyi rak: sovremennoe sostoyanie problemy. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii, 2012. 22;4: C. 5-16.

2. Ferlay J., Colombet M., Soerjomataram I., et al. the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937.

3. Biller L.H., Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669-685. doi:10.1001/jama.2021.0106.

4. Kaprin A. D., Starinskij V. V., Shahzadova A. O. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2019 godu [The state of oncological care to the population of Russia in 2019], 2020. (In Russian) Available at: https://glavonco.ru/cancer_register/Pomoshch'%202019.pdf @@Kaprin A. D., Starinskii V. V., Shakhzadova A. O. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2019 godu, 2020. https://glavonco.ru/cancer_register/Pomoshch'%202019.pdf

5. Siegel R.L., Miller K. D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3